SFP
AEGR

Santa Fe Partners’s Aegerion Pharmaceuticals AEGR Stock Holding History

Santa Fe Partners’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-31,093
Closed -$1.04M – 651
2014
Q3 		$1.04M Buy
+31,093
New +$965K 0.16% 251

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Santa Fe Partners's AEGR Position: Q4 2014 in Review

Santa Fe Partners sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2014, closing a stake of 31,093 shares — an estimated $1.04M sold.

Santa Fe Partners first reported a position in AEGR in Q3 2014 and held it in 1 quarter. The position peaked at $1.04M in Q3 2014. 95 funds tracked by Wall St. Rank hold AEGR as of Q4 2014.

  • Santa Fe Partners reported no remaining Aegerion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Santa Fe Partners sold 31,093 Aegerion Pharmaceuticals shares in Q4 2014, an estimated $1.04M.
  • Santa Fe Partners first reported a position in Aegerion Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Santa Fe Partners's Aegerion Pharmaceuticals position peaked at $1.04M in Q3 2014.
  • 95 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2014.

Based on Santa Fe Partners's 13F filing for Q4 2014, filed 13 Feb 2015.